|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Supplementary Table 1 - Clinical characteristics of patients at the time of LT in the different subgroups  considered (Nivolumab/Bevacizumab, Tyrosine Kinase Inhibitors – TKI, or Best Supportive Care - BSC). | | | | | |
| **Features** | **All**  **(n=22)** | **Nivo/Beva**  **(n=5)** | **TKIs**  **(n=13)** | **BSC**  **(n=4)** | **p** |
| **Age (mean, SD)** | 59.1 ±7.9 | 55.8±7.6 | 60.2 ± 9.1 | 60 ± 2.8 | 0.791 |
| **Gender (male, %)** | 17 (77.3) | 3 (60.0) | 11 (91.7) | 3 (75.0) | 0.211 |
| **Blood type** |  |  |  |  |  |
| A  B  AB  0 | 7 (31.8)  4 (18.1)  2 (9.0)  9 (40.9) | 2 (40.0)  -  -  3 (60.0) | 5 (38.4)  2 (15.3)  2 (15.3)  4 (30.7) | 1 (25.0)  2 (50.0)  -  1 (25.0) | 0.466 |
| **Etiology of Liver disease (n, %)**   * HCV * HBV * Other causes | 10 (45.5)  7 (31.8)  5 (22.7) | 2 (40.0)  1 (20.0)  2 (40.0) | 6 (46.2)  4 (30.7)  3 (23.1) | 2 (50.0)  2 (50.0)  0 | 0.821 |
| **Edmondson-Steiner grading (n, %)** |  |  |  |  |  |
| **1** |  |  | 1 (7.7) |  |  |
| 2 | 10 (45.4) | 3 (75.0) | 6 (46.15) | 0 | 0.114 |
| 3 | 12 (54.5) | 1(25.0) | 6 (46.15) | 4 (100.0) |
| **Bilirubin (mg/dL)(mean, SD)** | 0.5±0.2 | 0.56 ± 0.25 | 0.45 ± 0.15 | 0.61 ± 0.26 | 0.441 |
| **Albumin (g/dL)(mean, SD)** | 3.8±0.43 | 3.9 ± 0.54 | 3.7 ± 0.40 | 4 ± 0.42 | 0.249 |
| **AFP (ng/mL)(mean, SD)** | 138±326 | 43 ± 35 | 149 ± 403 | 273 ± 242 | 0.118 |
| **Down staged before LT** | 21 (95.4) | 5 (29.4) | 10 (58.8) | 2 (11.8) | 0.157 |
| **Pre-transplant downstaging modalities (n, %)**   * None * Resection * Loco-regional treatments * Combined | 5 (22.7)  4 (18.1)  9 (40.9)  4 (18.1) | 0  1 (20.0)  3 (60.0)  1 (20.0) | 2 (15.4)  3 (23.1)  5 (38.4)  3 (23.1) | 3 (75.0)  0  1 (25.0)  0 | 0.125 |
| **“Milan-in” at LT time (n, %)** | 17 (77.3) | 4 (80.0) | 9 (75.0) | 4 (80.0) | 0.962 |
| **Presence of viable tumor at explant (n, %)** | 17 (77.2) | 3 (60.0) | 10 (76.9) | 4 (100.0) | 0.295 |
| **Presence of extra-hepatic tumor at LT (n, %)** | 5 (13.6) | 2 (20.0) | 1 (7.6) | 2 (11.8) | 0.365 |
| **Re-transplant (n, %)** | 2 (9.0) | 1 (20.0) | 1 (7.6) | - | 0.577 |
| **Immunosuppressive regimen at transplant (n, %)**   * Everolimus * Sirolimus * Tacrolimus * Mycophenolate | 12 (54.5)  5 (22.7)  4 (18.1)  1 (4.5) | 3 (60.0)  2 (40.0) | 6 (46.1)  2 (46.1)  3 (23.0)  1 (7.7) | 3 (75.0)  1 (25.0)  1 (25.0) | 0.369 |